Condensed Consolidated Statements of Changes in Equity (Statement) - USD ($) $ in Thousands		Total		Common Units		Accumulated Other Comprehensive Income	Retained Earnings	Noncontrolling Interests
Redeemable noncontrolling interests, beginning balance at Dec. 31, 2022		$ 10,796
Increase (Decrease) in Temporary Equity [Roll Forward]
Net loss attributable to redeemable noncontrolling interests		(788)
Redeemable noncontrolling interests, ending balance at Mar. 31, 2023		10,008
Balance, beginning of period (in shares) at Dec. 31, 2022	[1]			482,726,544
Balance, beginning of period at Dec. 31, 2022		1,039,510		$ 510,968		$ 26,533	$ 101,549	$ 400,460
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income attributable to Ardent Health Partners, Inc.		4,143					4,143
Net income attributable to noncontrolling interests		20,427						20,427
Other comprehensive loss		(4,564)				(4,564)
Distributions to noncontrolling interests		(12,555)						(12,555)
Vesting of Class C Units (in shares)	[1]			587,053
Vesting of Class C Units		360		$ 360
Balance, ending of period (in shares) at Mar. 31, 2023	[1]			483,313,597
Balance, ending of period at Mar. 31, 2023		1,047,321		$ 511,328		21,969	105,692	408,332
Redeemable noncontrolling interests, beginning balance at Dec. 31, 2022		10,796
Redeemable noncontrolling interests, ending balance at Jun. 30, 2023		9,038
Balance, beginning of period (in shares) at Dec. 31, 2022	[1]			482,726,544
Balance, beginning of period at Dec. 31, 2022		1,039,510		$ 510,968		26,533	101,549	400,460
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income attributable to Ardent Health Partners, Inc.		37,219
Other comprehensive loss		25
Balance, ending of period (in shares) at Jun. 30, 2023	[1]			483,871,610
Balance, ending of period at Jun. 30, 2023		1,063,490		$ 496,520		26,558	138,768	401,644
Redeemable noncontrolling interests, beginning balance at Mar. 31, 2023		10,008
Increase (Decrease) in Temporary Equity [Roll Forward]
Net loss attributable to redeemable noncontrolling interests		(970)
Redeemable noncontrolling interests, ending balance at Jun. 30, 2023		9,038
Balance, beginning of period (in shares) at Mar. 31, 2023	[1]			483,313,597
Balance, beginning of period at Mar. 31, 2023		1,047,321		$ 511,328		21,969	105,692	408,332
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income attributable to Ardent Health Partners, Inc.		33,076					33,076
Net income attributable to noncontrolling interests		23,600						23,600
Other comprehensive loss		4,589				4,589
Distributions to noncontrolling interests		(19,254)						(19,254)
Redemption of equity attributable to noncontrolling interests		26,024		$ 14,990				11,034
Vesting of Class C Units (in shares)	[1]			558,013
Vesting of Class C Units		182		$ 182
Balance, ending of period (in shares) at Jun. 30, 2023	[1]			483,871,610
Balance, ending of period at Jun. 30, 2023		1,063,490		$ 496,520		26,558	138,768	401,644
Redeemable noncontrolling interests, beginning balance at Dec. 31, 2023		7,302
Increase (Decrease) in Temporary Equity [Roll Forward]
Net loss attributable to redeemable noncontrolling interests		(2,285)
Redeemable noncontrolling interests, ending balance at Mar. 31, 2024		$ 5,017
Balance, beginning of period (in shares) at Dec. 31, 2023		484,922,828		484,922,828	[2]
Balance, beginning of period at Dec. 31, 2023		$ 1,075,014	[3]	$ 496,882		18,561	155,453	404,118
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income attributable to Ardent Health Partners, Inc.		27,047					27,047
Net income attributable to noncontrolling interests		21,089						21,089
Other comprehensive loss		703				703
Distributions to noncontrolling interests		(14,256)						(14,256)
Vesting of Class C Units (in shares)	[2]			464,853
Vesting of Class C Units		512		$ 512
Balance, ending of period (in shares) at Mar. 31, 2024	[2]			485,387,681
Balance, ending of period at Mar. 31, 2024		1,110,109		$ 497,394		19,264	182,500	410,951
Redeemable noncontrolling interests, beginning balance at Dec. 31, 2023		7,302
Redeemable noncontrolling interests, ending balance at Jun. 30, 2024		$ 3,668
Balance, beginning of period (in shares) at Dec. 31, 2023		484,922,828		484,922,828	[2]
Balance, beginning of period at Dec. 31, 2023		$ 1,075,014	[3]	$ 496,882		18,561	155,453	404,118
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income attributable to Ardent Health Partners, Inc.		69,817
Other comprehensive loss		$ (1,552)
Balance, ending of period (in shares) at Jun. 30, 2024		485,909,683		485,909,683	[2]
Balance, ending of period at Jun. 30, 2024		$ 1,158,989	[3]	$ 497,620		17,009	225,270	419,090
Redeemable noncontrolling interests, beginning balance at Mar. 31, 2024		5,017
Increase (Decrease) in Temporary Equity [Roll Forward]
Net loss attributable to redeemable noncontrolling interests		(1,349)
Redeemable noncontrolling interests, ending balance at Jun. 30, 2024		3,668
Balance, beginning of period (in shares) at Mar. 31, 2024	[2]			485,387,681
Balance, beginning of period at Mar. 31, 2024		1,110,109		$ 497,394		19,264	182,500	410,951
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income attributable to Ardent Health Partners, Inc.		42,770					42,770
Net income attributable to noncontrolling interests		25,540						25,540
Other comprehensive loss		(2,255)				(2,255)
Distributions to noncontrolling interests		(17,401)						(17,401)
Vesting of Class C Units (in shares)	[2]			522,002
Vesting of Class C Units		$ 226		$ 226
Balance, ending of period (in shares) at Jun. 30, 2024		485,909,683		485,909,683	[2]
Balance, ending of period at Jun. 30, 2024		$ 1,158,989	[3]	$ 497,620		$ 17,009	$ 225,270	$ 419,090

[1] (*) See Note 1, Description of the Business and Basis of Presentation - Initial Public Offering and Corporate Conversion, for further discussion.

[2] (*) See Note 1, Description of the Business and Basis of Presentation - Initial Public Offering and Corporate Conversion, for further discussion.

[3] As of June 30, 2024 and December 31, 2023, the unaudited condensed consolidated balance sheet included total liabilities of consolidated variable interest entities of $317.1 million and $337.8 million, respectively. Refer to Note 2, Summary of Significant Accounting Policies, for further discussion.